<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38509608</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2524-3489</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>21</Day></PubDate></JournalIssue><Title>Neurological research and practice</Title><ISOAbbreviation>Neurol Res Pract</ISOAbbreviation></Journal><ArticleTitle>Randomized controlled double-blind trial of methylprednisolone versus placebo in patients with post-COVID-19 syndrome and cognitive deficits: study protocol of the post-corona-virus immune treatment (PoCoVIT) trial.</ArticleTitle><Pagination><StartPage>16</StartPage><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s42466-024-00311-w</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Post-COVID-19 Syndrome (PCS) includes neurological manifestations, especially fatigue and cognitive deficits. Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation are discussed as potential pathophysiological mechanisms. The post-corona-virus immune treatment (PoCoVIT) trial is a phase 2a randomized, controlled, double-blind trial designed to evaluate the effect of methylprednisolone versus placebo on cognitive impairment in PCS. This trial is designed based on the hypothesised autoimmunological pathogenesis and positive aberrations, employing a series of off-label applications.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Recruitment criteria include a diagnosis of PCS, a minimum age of 18&#xa0;years and self-reported cognitive deficits at screening. A total of 418 participants will be randomly assigned to either verum or placebo intervention in the first phase of the trial. The trial will consist of a first trial phase intervention with methylprednisolone versus placebo for six weeks, followed by a six-week treatment interruption period. Subsequently, an open second phase will offer methylprednisolone to all participants for six weeks. Outpatient follow-up visits will take place two weeks after each trial medication cessation. The third and final follow-up, at week 52, will be conducted through a telephone interview. The primary outcome measures an intra-patient change of 15 or more points in the memory satisfaction subscale of the Multifactorial Memory Questionnaire (MMQ) from baseline to follow-up 1 (week 8). Key secondary outcomes include long-term intra-patient changes in memory satisfaction from baseline to follow-up 2 (week 20), changes in other MMQ subscales (follow-up 1 and 2), and changes in neuropsychological and cognitive scores, along with assessments through questionnaires focusing on quality of life, fatigue, and mood over the same periods. Exploratory outcomes involve molecular biomarkers variations in serum and cerebrospinal fluid, as well as structural and functional brain magnetic resonance imaging (MRI) parameters changes related to cognition.</AbstractText><AbstractText Label="PERSPECTIVE" NlmCategory="CONCLUSIONS">This trial aims to contribute novel evidence for treating patients with PCS, with a primary focus on those manifesting cognitive deficits. By doing so, it may enhance comprehension of the underlying pathophysiological mechanisms, thereby facilitating biomarker research to advance our understanding and treatment of patients with PCS.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Franke</LastName><ForeName>Christiana</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5609-2472</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9; Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany. christiana.franke@charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raeder</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9; Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boesl</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9; Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bremer</LastName><ForeName>Benno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9; Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Lucas C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9; Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerhard</LastName><ForeName>Ameli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9; Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckert</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9; Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quitschau</LastName><ForeName>Anneke</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9; Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pohrt</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Institute of Biometry and Clinical Epidemiology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9;platz 1, 10117, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burock</LastName><ForeName>Susen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Clinical Trial Office, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruckert</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Clinical Trial Office, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheibenbogen</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Medical Immunology, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pr&#xfc;&#xdf;</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9;platz 1, 10117, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen (DZNE), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Audebert</LastName><ForeName>Heinrich J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt Universit&#xe4;t zu Berlin, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9; Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>01EP2201</GrantID><Agency>Bundesministerium f&#xfc;r Bildung, Wissenschaft, Forschung und Technologie</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurol Res Pract</MedlineTA><NlmUniqueID>101767802</NlmUniqueID><ISSNLinking>2524-3489</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Glucocorticoids</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Methylprednisolone</Keyword><Keyword MajorTopicYN="N">Pathophysiology</Keyword><Keyword MajorTopicYN="N">Placebo-controlled trial protocol</Keyword><Keyword MajorTopicYN="N">Post-COVID</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><CoiStatement>All authors are employed at Charit&#xe9;- Universit&#xe4;tsmedizin Berlin. All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>21</Day><Hour>0</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38509608</ArticleId><ArticleId IdType="pmc">PMC10956230</ArticleId><ArticleId IdType="doi">10.1186/s42466-024-00311-w</ArticleId><ArticleId IdType="pii">10.1186/s42466-024-00311-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Buzgau A, Cheng AC, de Jong M, Detry M, Estcourt L, Fitzgerald M, Summers C. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317&#x2013;1329. doi: 10.1001/jama.2020.17022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17022</ArticleId><ArticleId IdType="pmc">PMC7489418</ArticleId><ArticleId IdType="pubmed">32876697</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JH, Lin JJ, Doernberg M, Stone K, Navis A, Festa JR, Wisnivesky JP. Assessment of cognitive function in patients after COVID-19 infection. JAMA Network Open. 2021;4(10):e2130645. doi: 10.1001/jamanetworkopen.2021.30645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.30645</ArticleId><ArticleId IdType="pmc">PMC8536953</ArticleId><ArticleId IdType="pubmed">34677597</ArticleId></ArticleIdList></Reference><Reference><Citation>Boesl F, Audebert H, Endres M, Pruss H, Franke C. A neurological outpatient clinic for patients with post-COVID-19 syndrome - A report on the clinical presentations of the first 100 patients. Frontiers in Neurology. 2021;12:738405. doi: 10.3389/fneur.2021.738405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.738405</ArticleId><ArticleId IdType="pmc">PMC8481602</ArticleId><ArticleId IdType="pubmed">34603189</ArticleId></ArticleIdList></Reference><Reference><Citation>Buuren S, Groothuis-Oudshoorn C. MICE: multivariate imputation by chained equations in R. Journal of Statistical Software. 2011 doi: 10.18637/jss.v045.i03.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v045.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, Rodrigues NB, Subramaniapillai M, Di Vincenzo JD, Cao B, Lin K, Mansur RB, Ho RC, Rosenblat JD, Miskowiak KW, Vinberg M, Maletic V, McIntyre RS. Fatigue and cognitive impairment in post-COVID-19 syndrome: A systematic review and meta-analysis. Brain, Behavior, and Immunity. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: A meta-analysis and systematic review. Journal of Infectious Diseases. 2022;226(9):1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Delamarre L, Gollion C, Grouteau G, Rousset D, Jimena G, Roustan J, Gaussiat F, Aldige E, Gaffard C, Duplantier J, Martin C, Fourcade O, Bost C, Fortenfant F, Delobel P, Martin-Blondel G, Pariente J, Bonneville F, Geeraerts T, Neuro ICURG. COVID-19-associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network. Journal of Neurology, Neurosurgery and Psychiatry. 2020;91(9):1004&#x2013;1006. doi: 10.1136/jnnp-2020-323678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323678</ArticleId><ArticleId IdType="pmc">PMC7476305</ArticleId><ArticleId IdType="pubmed">32651243</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan EP, McKeon A, Lennon VA, Boeve BF, Trenerry MR, Tan KM, Drubach DA, Josephs KA, Britton JW, Mandrekar JN, Lowe V, Parisi JE, Pittock SJ. Autoimmune dementia: Clinical course and predictors of immunotherapy response. Mayo Clinic Proceedings. 2010;85(10):881&#x2013;897. doi: 10.4065/mcp.2010.0326.</Citation><ArticleIdList><ArticleId IdType="doi">10.4065/mcp.2010.0326</ArticleId><ArticleId IdType="pmc">PMC2947960</ArticleId><ArticleId IdType="pubmed">20884824</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C, Boesl F, Goereci Y, Gerhard A, Schweitzer F, Schroeder M, Foverskov-Rasmussen H, Heine J, Quitschau A, Kandil FI, Schild AK, Finke C, Audebert HJ, Endres M, Warnke C, Pruss H. Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome. Brain, Behavior, and Immunity. 2023;109:139&#x2013;143. doi: 10.1016/j.bbi.2023.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2023.01.006</ArticleId><ArticleId IdType="pmc">PMC9841734</ArticleId><ArticleId IdType="pubmed">36657623</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C, Ferse C, Kreye J, Reincke SM, Sanchez-Sendin E, Rocco A, Steinbrenner M, Angermair S, Treskatsch S, Zickler D, Eckardt KU, Dersch R, Hosp J, Audebert HJ, Endres M, Ploner JC, Pruss H. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain, Behavior, and Immunity. 2021;93:415&#x2013;419. doi: 10.1016/j.bbi.2020.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.12.022</ArticleId><ArticleId IdType="pmc">PMC7834471</ArticleId><ArticleId IdType="pubmed">33359380</ArticleId></ArticleIdList></Reference><Reference><Citation>Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Landray MJ. Dexamethasone in hospitalized patients with COVID-19. The New England Journal of Medicine. 2021;384(8):693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilmot A, Maldonado Slootjes S, Sellimi A, Bronchain M, Hanseeuw B, Belkhir L, Yombi JC, De Greef J, Pothen L, Yildiz H, Duprez T, Fillee C, Anantharajah A, Capes A, Hantson P, Jacquerye P, Raymackers JM, London F, El Sankari S, van Pesch V. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. Journal of Neurology. 2021;268(3):751&#x2013;757. doi: 10.1007/s00415-020-10108-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10108-x</ArticleId><ArticleId IdType="pmc">PMC7391231</ArticleId><ArticleId IdType="pubmed">32734353</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology. 2021;19(3):141&#x2013;154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>McDaneld LM, Fields JD, Bourdette DN, Bhardwaj A. Immunomodulatory therapies in neurologic critical care. Neurocritical Care. 2010;12(1):132&#x2013;143. doi: 10.1007/s12028-009-9274-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12028-009-9274-0</ArticleId><ArticleId IdType="pubmed">19774497</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, Laue M, Schneider J, Brunink S, Greuel S, Lehmann M, Hassan O, Aschman T, Schumann E, Chua RL, Conrad C, Eils R, Stenzel W, Windgassen M, Heppner FL. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nature Neuroscience. 2021;24(2):168&#x2013;175. doi: 10.1038/s41593-020-00758-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje M, Iwasaki A. The neurobiology of long COVID. Neuron. 2022;110(21):3484&#x2013;3496. doi: 10.1016/j.neuron.2022.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.10.006</ArticleId><ArticleId IdType="pmc">PMC9537254</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder J, Lindqvist I, Rasmusson AJ, Husen E, Ronnelid J, Kumlien E, Rostami E, Virhammar J, Cunningham JL. Indirect immunofluorescence for detecting anti-neuronal autoimmunity in CSF after COVID-19&#x2014;Possibilities and pitfalls. Brain, Behavior, and Immunity. 2021;94:473&#x2013;474. doi: 10.1016/j.bbi.2021.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.02.013</ArticleId><ArticleId IdType="pmc">PMC9761871</ArticleId><ArticleId IdType="pubmed">33631284</ArticleId></ArticleIdList></Reference><Reference><Citation>Nittas V, Gao M, West EA, Ballouz T, Menges D, Wulf Hanson S, Puhan MA. Long COVID through a public health lens: An umbrella review. Public Health Reviews. 2022;43:1604501. doi: 10.3389/phrs.2022.1604501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/phrs.2022.1604501</ArticleId><ArticleId IdType="pmc">PMC8963488</ArticleId><ArticleId IdType="pubmed">35359614</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunez-Castilla J, Stebliankin V, Baral P, Balbin CA, Sobhan M, Cickovski T, Mondal AM, Narasimhan G, Chapagain P, Mathee K, Siltberg-Liberles J. Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 spike and human proteins. Viruses. 2022 doi: 10.3390/v14071415.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14071415</ArticleId><ArticleId IdType="pmc">PMC9318917</ArticleId><ArticleId IdType="pubmed">35891400</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibenbogen C, Bellmann-Strobl JT, Heindrich C, Wittke K, Stein E, Franke C, Pruss H, Pressler H, Machule ML, Audebert H, Finke C, Zimmermann HG, Sawitzki B, Meisel C, Toelle M, Krueger A, Aschenbrenner AC, Schultze JL, Beyer MD, Burock S. Fighting post-COVID and ME/CFS&#x2014;Development of curative therapies. Frontiers in Medicine. 2023;10:1194754. doi: 10.3389/fmed.2023.1194754.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1194754</ArticleId><ArticleId IdType="pmc">PMC10309204</ArticleId><ArticleId IdType="pubmed">37396922</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Bartley CM, Chow RD, Ngo TT, Jiang R, Zamecnik CR, Dandekar R, Loudermilk RP, Dai Y, Liu F, Sunshine S, Liu J, Wu W, Hawes IA, Alvarenga BD, Huynh T, McAlpine L, Rahman NT, Geng B, Farhadian SF. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep Med. 2021;2(5):100288. doi: 10.1016/j.xcrm.2021.100288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100288</ArticleId><ArticleId IdType="pmc">PMC8091032</ArticleId><ArticleId IdType="pubmed">33969321</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. The Lancet Infectious Diseases. 2022;22(4):e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotzny F, Filgueiras IS, Kedor C, Freitag H, Wittke K, Bauer S, Sepulveda N, Mathias da Fonseca DL, Baiocchi GC, Marques AHC, Kim M, Lange T, Placa DR, Luebber F, Paulus FM, De Vito R, Jurisica I, Schulze-Forster K, Paul F, Scheibenbogen C. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in post COVID syndrome correlate with symptom severity. Frontiers in Immunology. 2022;13:981532. doi: 10.3389/fimmu.2022.981532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.981532</ArticleId><ArticleId IdType="pmc">PMC9552223</ArticleId><ArticleId IdType="pubmed">36238301</ArticleId></ArticleIdList></Reference><Reference><Citation>Strupp M, Zingler VC, Arbusow V, Niklas D, Maag KP, Dieterich M, Bense S, Theil D, Jahn K, Brandt T. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. New England Journal of Medicine. 2004;351(4):354&#x2013;361. doi: 10.1056/NEJMoa033280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa033280</ArticleId><ArticleId IdType="pubmed">15269315</ArticleId></ArticleIdList></Reference><Reference><Citation>Troyer AK, Rich JB. Psychometric properties of a new metamemory questionnaire for older adults. Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. 2002;57(1):P19&#x2013;27. doi: 10.1093/geronb/57.1.p19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronb/57.1.p19</ArticleId><ArticleId IdType="pubmed">11773220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, Furst J, Schulze-Rothe S, Wallukat A, Honicke AS, Muller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. Journal of Translational Autoimmunity. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>